0000950170-24-010973.txt : 20240202 0000950170-24-010973.hdr.sgml : 20240202 20240202213135 ACCESSION NUMBER: 0000950170-24-010973 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240131 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Corcoran Andrea CENTRAL INDEX KEY: 0001296996 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39661 FILM NUMBER: 24593712 MAIL ADDRESS: STREET 1: 125 SUMMER STREET STREET 2: 16TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Atea Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001593899 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460574869 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 225 FRANKLIN STREET STREET 2: SUITE 2100 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-204-8109 MAIL ADDRESS: STREET 1: 225 FRANKLIN STREET STREET 2: SUITE 2100 CITY: BOSTON STATE: MA ZIP: 02110 4 1 ownership.xml 4 X0508 4 2024-01-31 0001593899 Atea Pharmaceuticals, Inc. AVIR 0001296996 Corcoran Andrea 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 false true false false See Remarks false Common Stock 2024-01-31 4 M false 44367 A 686051 D Common Stock 2024-02-01 4 S false 15843 3.8449 D 670208 D Restricted Stock Units 2024-01-31 4 M false 44367 0 D Common Stock 44367 88733 D Stock Option (Right to Buy) 4.16 2024-01-31 4 A false 200000 0 A 2034-01-30 Common Stock 200000 200000 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Includes 8,680 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan. Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 14, 2022. The original grant of 133,100 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028. Chief Financial Officer, Executive Vice President, Legal and Secretary /s/ Andrea Corcoran 2024-02-02